← Back to Screener
Moderna, Inc. Common Stock (MRNA)
Price$54.68
Favorite Metrics
Price vs S&P 500 (26W)90.36%
Price vs S&P 500 (4W)-2.27%
Market Capitalization$21.43B
All Metrics
Book Value / Share (Quarterly)$21.95
P/TBV (Annual)1.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-53.44%
Cash Flow / Share (Quarterly)$-5.27
Price vs S&P 500 (YTD)81.35%
Gross Margin (TTM)70.32%
Net Profit Margin (TTM)-145.16%
EPS (TTM)$-7.26
10-Day Avg Trading Volume5.24M
EPS Excl Extra (TTM)$-7.26
Revenue Growth (5Y)19.34%
EPS (Annual)$-7.25
ROI (Annual)-30.39%
Gross Margin (Annual)70.32%
Net Profit Margin (5Y Avg)-42.91%
Cash / Share (Quarterly)$14.72
Revenue Growth QoQ (YoY)-29.81%
ROA (Last FY)-22.87%
Revenue Growth TTM (YoY)-39.93%
EBITD / Share (TTM)$-7.33
ROE (5Y Avg)6.13%
Operating Margin (TTM)-158.13%
Cash Flow / Share (Annual)$-5.27
P/B Ratio2.48x
P/B Ratio (Quarterly)1.33x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)10.02x
ROA (TTM)-22.95%
EV / EBITDA (TTM)22.07x
EPS Incl Extra (Annual)$-7.25
Current Ratio (Annual)3.29x
Quick Ratio (Quarterly)3.08x
3-Month Avg Trading Volume10.34M
52-Week Price Return102.46%
EV / Free Cash Flow (Annual)2.54x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$21.84
P/S Ratio (Annual)11.02x
Asset Turnover (Annual)0.16x
52-Week High$59.55
Operating Margin (5Y Avg)-44.21%
EPS Excl Extra (Annual)$-7.25
CapEx CAGR (5Y)24.70%
Tangible BV CAGR (5Y)98.20%
26-Week Price Return94.34%
Quick Ratio (Annual)3.08x
13-Week Price Return60.34%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)3.29x
Enterprise Value$19,469.414
Revenue / Share Growth (5Y)18.85%
Asset Turnover (TTM)0.16x
Book Value / Share Growth (5Y)27.87%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)4.27x
Pretax Margin (Annual)-142.39%
Cash / Share (Annual)$14.72
3-Month Return Std Dev76.37%
Gross Margin (5Y Avg)72.34%
Net Income / Employee (TTM)$-1
ROE (Last FY)-32.62%
EPS Basic Excl Extra (Annual)$-7.25
P/FCF (TTM)24.05x
Receivables Turnover (TTM)7.17x
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-7.26
Receivables Turnover (Annual)7.17x
ROI (TTM)-29.50%
P/S Ratio (TTM)11.02x
Pretax Margin (5Y Avg)-37.96%
Revenue / Share (Annual)$5.00
Tangible BV / Share (Annual)$21.84
Price vs S&P 500 (52W)72.63%
Year-to-Date Return83.99%
5-Day Price Return5.81%
EPS Normalized (Annual)$-7.25
ROA (5Y Avg)1.63%
Net Profit Margin (Annual)-145.16%
Month-to-Date Return6.81%
Cash Flow / Share (TTM)$-7.54
EBITD / Share (Annual)$-7.33
Operating Margin (Annual)-158.13%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)5.54%
LT Debt / Equity (Quarterly)0.07x
EPS Basic Excl Extra (TTM)$-7.26
P/TBV (Quarterly)1.34x
P/B Ratio (Annual)1.33x
Inventory Turnover (TTM)4.27x
Pretax Margin (TTM)-142.39%
Book Value / Share (Annual)$21.95
Price vs S&P 500 (13W)59.66%
Beta1.21x
P/FCF (Annual)4.68x
Revenue / Share (TTM)$4.96
ROE (TTM)-30.15%
52-Week Low$22.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.80
2.80
2.80
2.80
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
KRYSKrystal Biotech, Inc. Common Stock | 20.17x | 33.95% | 94.08% | — | $264.06 |
About
Moderna is a biotechnology company leveraging its validated mRNA platform to develop therapeutics across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company commercially validated its technology with its FDA-authorized COVID-19 vaccine in 2020. As of August 2025, Moderna maintains a pipeline of 35 mRNA candidates in clinical development.